Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07046923 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
240
Enrollment target
20
Study locations

NCT07046923 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 240 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07046923, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Conditions Studied

Carcinoma, Non-Small Cell Lung Triple Negative Breast Cancer Neoplasm Metastasis Small Cell Lung Carcinoma Endometrial Neoplasms

Interventions

  • DRUG LY4175408

Study Locations (20)

Other

  • Centre Leon Berard - Lyon
  • Institut Gustave Roussy - Villejuif
  • Kyoto University Hospital - Kyoto
  • National Cancer Center Hospital - Tokyo
  • Cancer Institute Hospital of JFCR - Tokyo

Florida

  • Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute - Orlando
  • Florida Cancer Specialists - Sarasota - Sarasota

New York

  • Columbia University - New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York

California

  • Stanford Cancer Center - Stanford

Illinois

  • The University of Chicago Medical Center (UCMC) - Chicago

Indiana

  • Community Health Network - Indianapolis

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-07-28
Est. Completion 2030-07
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07046923

The ClinicalTrials.gov registry entry for NCT07046923 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (25% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which LY4175408 is the first listed.

NCT07046923 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07046923 about?

NCT07046923 is a clinical study titled "A Study of LY4175408 in Participants With Advanced Cancer". The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could ...

What is the current status of trial NCT07046923?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2025-07-28. Estimated completion is 2030-07.

What conditions does trial NCT07046923 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Triple Negative Breast Cancer, Neoplasm Metastasis, Small Cell Lung Carcinoma, Endometrial Neoplasms.

What interventions are being tested in trial NCT07046923?

The interventions under investigation include: LY4175408 (DRUG).

Who is sponsoring clinical trial NCT07046923?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07046923 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Triple Negative Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.